Cardiac Dimensions said yesterday a new cost-utility study of its Carillon mitral valve shows it to be a cost-effective alternative when compared to optimal medical treatment for treating functional mitral regurgitation.
The study was published in the journal BMC Cardiovascular Disorders, and analyzed data from the Titan clinical trial.
The study reported an incremental cost-effectiveness ratio of $17,435 (EU €15,533) per quality-adjusted life year, the company said. A cost under $39,287 (EU €35,000) is reported as typically cost-effective, according to the Kirkland, Wash.-based company.
“In multiple clinical trials, Carillon has demonstrated significant reductions in FMR and improvement in heart failure symptoms. This analysis takes the next step in projecting that these benefits result in the cost effectiveness of the therapy. This positive assessment has substantial implications in terms of the utility and accessibility of the therapy,” study co-author Dr. Michael Haude of Neuss, Germany’s Lukaskrankenhaus said in a press release.
The Carillon mitral contour system is a percutaneus mitral annuloplasty treatment that consists of a distal anchor and proximal anchor connected by a shaping ribbon that uses the heart’s veinous anatomy to reshape the mitral annulus, according to the company.
In June, Cardiac Dimensions launched a 120-patient clinical trial of its Carillon device. Patients are slated to be randomized on a 3:1 basis to receive the Carillon device and optimal drug treatment, or optimal drug treatment alone, the company said.